Revenue - Schedule of GTN Product Revenue, Net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Gross To Net Sales Adjustment Rollforward [Roll Forward]
Balance as of March 31, 2026	$ 12,549	$ 12,039	$ 10,678	$ 17,489
GTN accruals for current period	6,561	5,924	13,754	11,979
Prior period adjustments	(258)	(241)	(679)	(773)
Credits, payments and reclassifications	(4,525)	(3,540)	(9,426)	(14,513)
Balance as of June 30, 2026	14,327	14,182	14,327	14,182
Gross To Net Sales Adjustment [Abstract]
Accounts receivable, net	1,607		1,607		$ 1,658
Other current and non-current liabilities	12,720		12,720		9,020
Gross to net sales adjustment	14,327	14,182	14,327	14,182	10,678
Discarded Drug Rebate
Gross To Net Sales Adjustment Rollforward [Roll Forward]
Balance as of March 31, 2026	10,175	9,672	7,964	15,103
GTN accruals for current period	2,058	2,020	4,269	3,969
Prior period adjustments	0	0	0	(200)
Credits, payments and reclassifications	0	0	0	(7,180)
Balance as of June 30, 2026	12,233	11,692	12,233	11,692
Gross To Net Sales Adjustment [Abstract]
Gross to net sales adjustment	12,233	11,692	12,233	11,692	7,964
Other Adjustments
Gross To Net Sales Adjustment Rollforward [Roll Forward]
Balance as of March 31, 2026	2,374	2,367	2,714	2,386
GTN accruals for current period	4,503	3,904	9,485	8,010
Prior period adjustments	(258)	(241)	(679)	(573)
Credits, payments and reclassifications	(4,525)	(3,540)	(9,426)	(7,333)
Balance as of June 30, 2026	2,094	2,490	2,094	2,490
Gross To Net Sales Adjustment [Abstract]
Gross to net sales adjustment	$ 2,094	$ 2,490	$ 2,094	$ 2,490	$ 2,714